Modified GRF (1-29) + GHRP-6 - Spartan 3

1 Identity

Fixed-ratio two-component article: two synthetic C-terminally amidated peptides, co-lyophilized. which carries the trade misnomer for the 29-mer into the blend title. and often as "CJC-1295 no DAC + GHRP-6". Market names are recorded exactly as found and are not adopted as identity statements. SPARTAN 1 IS A different article and is a separate record: it substitutes hexarelin, the 2-methyl-indole congener of GHRP-6, 14.02 Da heavier, and the two blends cannot be told apart by amino acid analysis, for the reason set out under the testing panel.

Contains Modified GRF (1-29) + GHRP-6

Sequence

Per component; each component's full identity lives on its own record and is cross-referenced here rather than restated. Component A, Modified GRF (1-29): Y-(D-A)-DAIFTQSYRKVLAQLSARKLLQDILSR-NH2, 29 residues, the C-terminus A primary carboxamide and not a free acid, with four substitutions against native human GHRH(1-29) — D-Ala2, Gln8, Ala15 and Leu27. The Leu27 substitution removes the only sulfur atom in the native sequence, so any sulfur in an elemental result or an isotope pattern indicates sermorelin-family contamination. Component B, GHRP-6: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH2, six residues, all six constitutionally proteinogenic but two D-configured. Two indole side chains make the solid photolabile and oxidation-sensitive, and the imidazole of His1 makes the salt pH-sensitive in solution. Neither component contains cysteine, methionine, sulfur or a disulfide. Three D-configured positions across the article, which is what puts the whole into P3.

Molecular formula

Per component, never as a sum. Modified GRF (1-29) C152H252N44O42 as the C-terminal amide; GHRP-6 C46H56N12O6 as the free base, mono-acetate C48H60N12O8, tri-acetate C52H68N12O12. No combined formula is written: a mixture has no molecular formula, and a certificate printing one describes something that does not exist. Salt is stated per component — the institutional reference form of GHRP-6 is the tri-acetate at 1,053.19, of which about 82.9 percent is peptide, and net peptide content on a trifluoroacetate lot of the 29-mer typically runs 75 to 85 percent.

Average mass

Per component. Modified GRF (1-29) 3,367.954 Da; GHRP-6 873.032 Da as the free base, 933.08 as the mono-acetate, 1,053.19 as the tri-acetate. Worked example at 10 mg plus 10 mg, a 20 mg total nominal fill: 2.969 against 11.454 micromol, a 1.00-to-3.86 molar ratio out of a 1.0-to-1.0 mass ratio. Named comparators: hexarelin at 887.059, exactly 14.02 Da heavier and the substitution this article is most exposed to; CJC-1295 with DAC at 3,647.250; and sermorelin at 3,357.93, which contains one sulfur.

Monoisotopic mass

Per component. Modified GRF (1-29) 3,365.89358 Da neutral, observed multiply charged — [M+3H]3+ 1,122.97180, [M+4H]4+ 842.48067 — and reported as a deconvoluted neutral with the raw envelope shown. GHRP-6 872.4446 neutral, [M+H]+ 873.4519, [M+2H]2+ 437.2296; tri-acetate 1,052.5080 neutral. Hexarelin sits at 886.4602 neutral, 14.0157 Da heavier, and that separation is the single measurement that distinguishes this article from its hexarelin-containing sibling. Identity is confirmed against both expected neutrals in one run.

Salt / variant note

The hexarelin neighbor is the governing confusable, and the exposure on this article runs opposite to the one on its sibling: the risk here is hexarelin arriving mislabeled as GHRP-6, not GHRP-6 arriving in place of hexarelin. Each is a named specified impurity in the other, and the two are never processed on the same fill line without a cleaning-verification swab reported to the lot record. [D-Lys3]-GHRP-6 is cataloged separately by a reagent catalog under its own item number and is the near-name collision to watch on an order. The name fork on the 29-mer: "CJC-1295 no DAC" at 3,367.954 against CJC-1295 (DAC:GRF) at 3,647.250, two different molecules under one trade habit of naming. GHRP-6 salt: free base 873.032, mono-acetate 933.08, tri-acetate 1,053.19. Ratio: no standard exists.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P3 — panel definitionfor both components, run per component rather than once on the mixture. Chiral amino acid analysis must report D-Ala2 on the 29-mer and D-Trp2 and D-Phe5 on the hexapeptide, which is why a chiral method is mandatory here rather than optional. Each component is released against its full single-article P3 specification on the input material before blending, and hexarelin is carried as a named specified impurity of the GHRP-6 component rather than as an unspecified peak. The limit of amino acid analysis on this article is stated rather than left to be discovered: with both indoles destroyed in standard hydrolysis, GHRP-6 and hexarelin present the identical recoverable profile of one alanine, one phenylalanine, one histidine and one lysine, so amino acid analysis cannot distinguish this article from its hexarelin-containing sibling, and the certificate rests on the 14.0157 Da monoisotopic separation or on a modified hydrolysis. Alanine is a unique marker for the 29-mer against ipamorelin but not against GHRP-6, GHRP-2 or hexarelin, so the per-component deconvolution is worked out for this pairing rather than carried across from a neighboring blend

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component, is graded on that component's record and is cross-referenced from here rather than restated. GHRP-6 is the prototype of the growth hormone-releasing peptide series and its literature is the oldest in that series. The Modified GRF (1-29) literature is the GHRH-analog body of work, complicated throughout by the naming problem recorded above, so a citation must be checked against the sequence rather than against the title it was published under. None of it is literature about this mixture: no published study of this fixed two-component combination was located.

4 Storage & specification

Storage

White to off-white co-lyophilized solid in a screw-cap amber borosilicate vial with a PTFE-lined closure, with a desiccant sachet in the secondary pack — a laboratory-chemical presentation, non-sterile, with no sterility claim and no stoppered-and-crimped injection format. Store at -20 degrees C plus or minus 5 degrees C, tightly closed, desiccated, and protected from light as A specification rather than A PRECAUTION, the GHRP-6 component carrying two indole side chains. The imidazole of His1 makes the reconstituted solution pH-sensitive, so the diluent is named on the label rather than left to the user. Neither component contains cysteine, methionine or a disulfide, so inert headspace is not required, and its absence here is a considered position rather than an omission. Reconstituted solution is aliquoted single-use and held at -80 degrees C.

Shelf life

Provisional 24 months at -20 degrees C plus or minus 5 degrees C, desiccated and protected from light, from the date of QA release — both component intervals being 24 months — and provisional pending this company's own data. The protocol runs real-time pulls at 3, 6, 9 and 12 months at the labeled condition, plus 6 months accelerated at 40 degrees C and 75 percent relative humidity, with an ICH Q1B photostability challenge run once on the launch lot in the final container. Stability-indicating attributes: the sum of indole-oxidation products at plus 16 and plus 32 Da, aggregate content by SE-HPLC, hexarelin as a named specified impurity, the des-amido free acid of each component, iso-aspartate on the 29-mer, per-component net content, the measured ratio, and water and counterion per component.